Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (512)	1/17/2000 2:59:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 52153

Peter, thanks for the comments. I re-examined the MEDX/ABGX charts and the rotting comments may apply to the trailing 30-week period after all. So in charts, as in all everything depends on the point of view -g- Your comments on the CRA/INCY example show how this armchair quarterbacking is a lot easier than the real thing. In retrospect it was a no-brainer to get into INCY as it could not possibly be so much cheaper than CRA. At the time, it was not clear if CRA's gain was INCY's (total) loss, at least if one did not have all the facts. BTW, when was the last time you had all the facts? -g- The flip side of this is miss-assigning your investment to the wrong subsector. Gee, I thought that AIMM was a real hot genomics outfit; read about it in the internet. PB